Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-02-21 @ 11:18 PM
Study NCT ID:
NCT03624751
Status:
RECRUITING
Last Update Posted:
2018-08-10
First Post:
2018-05-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Sponsor:
Taichung Veterans General Hospital
Organization:
Study Overview
Official Title:
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
Status:
RECRUITING
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Detailed Description:
1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.
2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Inclusion ： Patient number: 500人
Inclusion criteria :
1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。
Exclusion criteria:
1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。
Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Inclusion ： Patient number: 500人
Inclusion criteria :
1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。
Exclusion criteria:
1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。
Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: